Promoted Content

Promoted Content

All

API

FDF

Price

Services

Excipients

Enquiries

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

Find Clinical Drug Pipeline Developments & Deals by Micreos Human Health

All Data

Filters

refresh

×

FILTER DATA :

Therapeutic Area

Study Phase

Country

News Type

Company

refresh

Companies By Therapeutic Area

Development Status

Micreos Human Health

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Netherlands

Post An Enquiry

Biofit 2020

Participation Not Confirmed

Update your events

Micreos Initiates Clinical Trial to Evaluate World’s First Endolysin-Drug as a Therapy for Atopic Dermatitis

Contact the Supplier

Lead Product(s): XZ.700

Therapeutic Area: Dermatology Product Name: XZ.700

Highest Development Status: Phase I/ Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 22, 2020

Details:

Micreos Human Health has enrolled the first patients in a Phase I/IIa, randomized, double-blind, placebo-controlled, parallel treated dose-ranging study to assess the safety and efficacy of XZ.700 in patients with mild to moderate atopic dermatitis.